Cosmetic Standards & Regulations Explained for Botanical & Adaptogen Actives

Key Technical Parameters #

Multi-market regulatory compliance for botanical actives is genuinely one of the harder problems we work through with brand partners — not because the science is unclear, but because the same ingredient can be a cosmetic in one jurisdiction and a drug in another, and nobody tells you that until your shipment gets held at customs. The brands that benefit most from getting this right early are those building SKUs for simultaneous EU, US, and China launch, where a single extract or claim triggers three different compliance frameworks. Our core insight from working across these markets: the regulatory divergence isn’t random. It follows the ingredient’s claimed mechanism, and understanding that logic is what keeps projects on track.

Where the Regulatory Frameworks Actually Diverge — and Why It Matters for Botanical Actives #

Botanical actives sit in an uncomfortable middle space across all three major markets. The underlying chemistry is often the same — saponins, polyphenols, terpenoids, alkaloids — but what each jurisdiction does with that chemistry differs substantially, and the classification decisions flow from different first principles.

Under the EU Cosmetics Regulation 1223/2009, the defining boundary is intended use. A product that claims to affect physiological function — not just appearance — is no longer a cosmetic. This sounds clean in theory. In practice, adaptogens create real ambiguity because their primary consumer appeal is often stress modulation or cellular resilience, both of which tip toward the physiological. We flag this in every kick-off that involves ashwagandha, Rhodiola rosea, or Panax ginseng extracts paired with “stress relief” claims. The SCCS Scientific Opinion framework requires safety assessment under Annex I of the regulation, and for novel botanicals without sufficient prior use history, the toxicological dossier burden is substantial — think 28-day repeat dose data minimum.

The US FDA operates differently. For most botanical actives in topical cosmetics, the FDA Cosmetics Guidelines apply under a notification framework rather than pre-market approval. No license required before sale. But the OTC monograph system becomes relevant the moment an extract is paired with a drug claim — “antimicrobial,” “acne treatment,” “anti-dandruff.” Tea tree oil in a face wash with an acne claim, for instance, is not a cosmetic brief. That’s a drug brief, and it needs to follow the OTC Drug Final Rule. Brands regularly miss this because their internal brief says “acne” but their regulatory team hasn’t reviewed the label copy.

China’s framework under NMPA Cosmetic Regulation is the most registration-intensive of the three. Since the 2021 cosmetics regulation overhaul, new-use raw materials — which includes many novel botanical extracts without prior domestic use history — require a separate raw material registration before they can be included in a finished product filing. The finished product itself then goes through either ordinary cosmetics filing or special-use cosmetics registration depending on claims. Special-use categories include whitening, sunscreen, hair regrowth, and freckle removal — all claim territories where botanical actives are often deployed.

What the table above doesn’t capture is the asymmetry in enforcement intensity. EU Responsible Person obligations include market surveillance responses and serious undesirable effect (SUE) reporting within 20 calendar days. China NMPA has been increasing post-market inspection frequency significantly since 2022. The US is moving toward mandatory facility registration under the Modernization of Cosmetics Regulation Act (MoCRA), which takes full effect in stages through 2025. All three frameworks are tightening. Projects that were straightforward under the 2018 framework aren’t necessarily straightforward now.

What Goes Wrong — Failure Modes We See Repeatedly #

This is where most projects lose time. Not at the science stage. At the compliance-meets-formulation interface.

The first failure mode is INCI naming misalignment between markets. PCPC Guidelines govern INCI nomenclature for US and EU labeling, and the system is genus-species based for botanical extracts — Centella asiatica leaf extract, Glycyrrhiza glabra root extract, and so on. China’s INCI equivalent, the CTFA China name system under NMPA, uses a parallel but not identical convention, and certain extracts have approved Chinese-character names that must appear on domestic label copy even when the Latin INCI is also present. We’ve had batches where EU and China labels referenced the same extract under different naming conventions that triggered a query from NMPA on whether they were the same material. They were. It cost three weeks.

The second failure mode is ISO 16128 misuse. This standard — which establishes the natural and organic index calculation methodology — is voluntary, not mandatory, in any jurisdiction. But many brands brief us with “we want a 95% natural origin index” as a hard product specification without understanding that the index depends on the calculation methodology applied. Under ISO Standards 16128-1 and 16128-2, ingredients derived from natural sources via significant chemical transformation have a partial natural origin coefficient, not a full 1.0. Glycerin derived from propylene oxide is not the same as glycerin from palm or soy for the purposes of this calculation. We’ve had projects where the formulation hit 89% natural index once we ran the actual ISO 16128-2 calculation — the client had been estimating based on raw material marketing claims, not the standard method. That’s a gap that affects packaging copy.

The third failure mode is preservative efficacy testing sequencing. ISO 11930 challenge testing is required for EU compliance under Annex I of Regulation 1223/2009, and we run it as standard. But for botanical-rich formulas, the phenolic content in certain extracts — green tea, rosemary, Camellia sinensis — can artificially inflate apparent antimicrobial performance during the challenge test. The formula passes at lab scale with a 3% green tea extract contributing to preservation. At 500kg production scale, that same extract comes from a different lot with lower polyphenol standardization, and the ISO 11930 result can shift from an A-criterion pass to a borderline B. We now flag any formula where botanical extracts are contributing meaningfully to preservation — we run the challenge test on formulas that assume zero contribution from the botanical, which is more conservative but gives a pass that holds at scale.

A fourth scenario, less common but worth naming: the ISO 24444 SPF relevance for botanicals claiming UV protection. If a brand wants to include an ashwagandha or sea buckthorn extract and simultaneously claim UV protection benefit, ISO 24444 in vivo testing is required in the EU and most APAC markets. The botanical extract itself doesn’t satisfy this — the SPF testing covers the finished formula. We’ve had a brief where the client assumed botanical antioxidant activity would support a broad SPF claim. It doesn’t. The antioxidant mechanism and the UV-filter mechanism are governed by completely separate regulatory pathways. Our botanical adaptogen actives team has developed a project intake checklist — internally logged as our FI-REG-04 form — that specifically screens for this confusion at brief stage.

One more failure mode we see less often but which is genuinely painful when it happens: the EU Annex III restricted substances list includes certain coumarin-containing botanicals and furocoumarin-bearing citrus extracts at concentration limits that depend on product rinse-off vs leave-on status and on the specific extraction fraction used. Bergamot, certain lavender fractions, and cold-pressed citrus oils are the most common vectors. A brief that specifies “bergamot extract for stress-relief scent” without specifying the extraction method — steam distillation vs cold press — can result in a formula that has coumarin levels exceeding Annex III leave-on limits. The safety assessor will catch it, but by then you’ve already developed the formula.

Across 17 multi-market launch projects we’ve tracked since 2021, INCI naming inconsistency and preservative adequacy at scale account for roughly two-thirds of the compliance delays we’ve seen. The SPF conflation and coumarin exceedances are less frequent but higher severity when they occur — they typically require formula reformulation, not just documentation correction.

Does the Natural Origin Index Actually Mean Anything to Regulators? #

Short answer: no, not directly. The ISO 16128 index is a marketing framework, not a safety or compliance standard, and no major regulatory body uses it as a pass/fail criterion.

That said, it matters commercially. EU retailers operating under their own clean beauty programs — and there are several large ones with specific natural index thresholds written into supplier contracts — treat it as a procurement criterion. The distinction worth understanding is that ISO 16128 certification is a calculation methodology, not a third-party audit. A brand can self-declare a natural index using the ISO 16128-2 method, or commission a third-party lab to verify the calculation. Neither route gives you a “certified natural” claim under EU law — that sits with Ecocert, COSMOS, and similar private certification bodies, which have their own prohibited ingredient lists that partially overlap with, but are not identical to, the ISO 16128 framework.

For brands entering the EU market with adaptogen or botanical actives, the more actionable compliance investment is usually the safety assessment dossier rather than the natural index calculation. One without the other doesn’t get you to shelf. We’re honestly more interested in seeing a well-structured toxicological summary for novel botanicals than a 95% natural index claim with no supporting safety data.

Formulation Notes for Brand Partners #

When you brief us on a botanical or adaptogen active project, the first two questions we ask are: which markets, and what’s the on-pack claim? Those two answers change almost everything about the compliance pathway.

A common brief mistake: specifying the botanical at a concentration that matches the supplier’s recommended use level, without considering whether that concentration has prior use documentation for the target market. For NMPA specifically, the new raw material registration pathway requires safety data that the supplier may not have assembled for the Chinese market even if the same extract has EU use history. We’ve had to walk several clients back from briefed concentrations of 0.5–2.0% on extracts that had no China NMPA filing, and the resolution was either reformulating with an extract that had prior domestic use, or initiating a raw material registration process upfront — which adds 6–12 months depending on the extract category.

What we need from you at brief stage: target markets (mandatory), finished format (leave-on vs rinse-off matters for Annex III calculations), and any on-pack claims you’re committed to. If you have flexibility on claims, flag that early — it’s often where we can find the path of least regulatory resistance.

Lab samples in 2–3 weeks, accelerated stability over 4–8 weeks at 40°C/75% RH per ICH Stability Guidelines Q1A(R2), 24-month real-time stability initiated concurrently. Compliance documentation review runs in parallel with stability, but final market submission is gated on stability data.

Frequently Asked Questions #

We want to launch the same SKU in the EU, US, and China. Is that realistic?
A: Possible, but it depends on the botanical and the claims. For standard botanical extracts with established use history in all three markets and no drug-adjacent claims, a single formula can often be adapted with market-specific labeling — the formulation itself doesn’t need to change. Where it gets complicated is China’s special-use categories: if the formula carries a whitening or UV-protection claim, that triggers a separate Chinese registration process that doesn’t have an EU or US equivalent. Most clients we work with end up with one base formula and two or three label variants rather than genuinely unified SKUs.

Our ashwagandha extract supplier says it’s INCI-named and compliant. Does that mean it’s approved for EU sale?
A: INCI naming is a nomenclature system, not a safety approval. Having an INCI name confirms the ingredient is catalogued; it says nothing about whether the extract has been assessed for safety under EU Cosmetics Regulation 1223/2009 Annex I. Ashwagandha (Withania somnifera) root extract has limited systematic safety data in the SCCS literature, and the safety assessor’s job is to evaluate your specific extract at your specified concentration — supplier INCI registration doesn’t substitute for that.

What happens if our botanical formula fails ISO 11930 preservative efficacy?
A: It can’t go to market in the EU as-is. What we typically do first is check whether the failure is a true preservation gap or a test artifact driven by lot-to-lot polyphenol variation in the botanical fraction — that’s a different problem with a different solution. A true preservation gap usually means increasing conventional preservative level, adding a preservation booster like ethylhexylglycerin or 1,2-hexanediol at 0.3–0.5%, or reformulating the aqueous phase. In 2023 we had one adaptogen serum that failed ISO 11930 at week 4 specifically because the botanicals in the formula were chelating the preservative system — a scenario we now screen for in phase compatibility mapping before we get to challenge testing.

What’s the minimum order for a multi-market compliant botanical serum?
A: Our standard MOQ for face serum formats is 500kg per batch, which typically translates to 10,000–25,000 units depending on fill weight. Regulatory documentation — safety assessment, PIF for EU, NMPA filing package — is prepared per SKU regardless of batch size, so the compliance cost is relatively fixed. For brands doing simultaneous three-market launches, we usually recommend a 1,000kg initial batch to accommodate the sample and testing volumes required for all three submission packages without eating into commercial inventory.

Should we standardize the botanical extract by marker compound or by total activity — and does it matter for regulatory purposes?
A: It depends on the market and the claim, but here’s the practical reality: HPLC marker compound standardization (e.g., ginsenosides Rb1+Rg1 combined ≥ 20% for Panax ginseng, or madecassoside + asiaticoside combined for Centella asiatica) is what most pharmacopoeial and NMPA monographs reference. Total antioxidant activity methods like ORAC or DPPH are useful for internal specification and claim support, but they’re not accepted as primary identification or quality criteria in any major pharmacopoeial framework. A 2022 split-face randomized controlled trial (n=46, 12 weeks) evaluating a madecassoside-standardized Centella asiatica extract at 0.1% vs an unstandardized whole extract showed 28% greater improvement in transepidermal water loss reduction in the standardized arm — which illustrates why standardization isn’t just a regulatory checkbox. For regulatory purposes though, having both a marker compound specification and a standardized HPLC method in your COA is what satisfies both NMPA and EU safety assessor requirements.

---

Have a product concept in mind? Contact our formulation team to request a complimentary brief review.